These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 3141098)

  • 1. Pharmacokinetics of flecainide in patients with cirrhosis of the liver.
    McQuinn RL; Pentikäinen PJ; Chang SF; Conard GJ
    Clin Pharmacol Ther; 1988 Nov; 44(5):566-72. PubMed ID: 3141098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of flecainide acetate in patients with severe renal impairment.
    Williams AJ; McQuinn RL; Walls J
    Clin Pharmacol Ther; 1988 Apr; 43(4):449-55. PubMed ID: 3128417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral flecainide pharmacokinetics in patients with impaired renal function.
    Forland SC; Burgess E; Blair AD; Cutler RE; Kvam DC; Weeks CE; Fox JM; Conard GJ
    J Clin Pharmacol; 1988 Mar; 28(3):259-67. PubMed ID: 3129455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine.
    Razak TA; McNeil JJ; Sewell RB; Drummer OH; Smallwood RA; Conway EL; Louis WJ
    Clin Pharmacol Ther; 1990 Apr; 47(4):463-9. PubMed ID: 2328554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.
    Teunissen MW; Spoelstra P; Koch CW; Weeda B; van Duyn W; Janssens AR; Breimer DD
    Br J Clin Pharmacol; 1984 Nov; 18(5):707-15. PubMed ID: 6508980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects.
    Pentikäinen PJ; Välisalmi L; Himberg JJ; Crevoisier C
    J Clin Pharmacol; 1989 Mar; 29(3):272-7. PubMed ID: 2723115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide.
    Mikus G; Gross AS; Beckmann J; Hertrampf R; Gundert-Remy U; Eichelbaum M
    Clin Pharmacol Ther; 1989 May; 45(5):562-7. PubMed ID: 2498026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of zinc supplementation on oxidative drug metabolism in patients with hepatic cirrhosis.
    Barry MG; Macmathuna P; Younger K; Keeling PW; Feely J
    Br J Clin Pharmacol; 1991 Apr; 31(4):488-91. PubMed ID: 2049261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function.
    Forland SC; Cutler RE; McQuinn RL; Kvam DC; Miller AM; Conard GJ; Parish S
    J Clin Pharmacol; 1988 Aug; 28(8):727-35. PubMed ID: 3145942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of flecainide.
    Conard GJ; Ober RE
    Am J Cardiol; 1984 Feb; 53(5):41B-51B. PubMed ID: 6364769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
    Baririan N; Van Obbergh L; Desager JP; Verbeeck RK; Wallemacq P; Starkel P; Horsmans Y
    Clin Pharmacokinet; 2007; 46(3):261-70. PubMed ID: 17328584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of hepatic disease on the disposition of moricizine in humans.
    Pieniaszek HJ; Davidson AF; McEntegart CM; Quon CY; Sampliner RE; Mayersohn M
    Biopharm Drug Dispos; 1994 Apr; 15(3):243-52. PubMed ID: 7880984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of encainide in patients with cirrhosis.
    Wensing G; Mönig H; Ohnhaus EE; Hoensch HP
    Cardiovasc Drugs Ther; 1991 Aug; 5(4):733-9. PubMed ID: 1909559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.
    Bauer LA; O'Sullivan T; Reiss WG; Horn JR; Opheim K; Strandness DE; Carithers RL
    Br J Clin Pharmacol; 1994 Apr; 37(4):375-81. PubMed ID: 8018459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue zinc status and drug elimination in patients with chronic liver disease.
    Barry M; Keeling PW; Feely J
    Clin Sci (Lond); 1990 Jun; 78(6):547-9. PubMed ID: 2165886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipyrine kinetics in patients with primary biliary cirrhosis.
    von Moltke LL; Abernethy DR; Kaplan MM; Greenblatt DJ
    J Clin Pharmacol; 1993 Jan; 33(1):75-7. PubMed ID: 8429118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diurnal variability of hepatic clearance of antipyrine and Tc-99m-HIDA in healthy persons and in those with liver diseases. I].
    Hartleb M; Markiewicz A; Rudzki K; Nowak S; Bołdys H; Kacperek T
    Pol Arch Med Wewn; 1987 Jun; 77(6):264-9. PubMed ID: 3271278
    [No Abstract]   [Full Text] [Related]  

  • 18. A comparison between antipyrine and aminopyrine blood clearances.
    Kawasaki S; Imamura H; Kokudo N; Bandai Y; Sanjo K; Idezuki Y
    Hepatogastroenterology; 1992 Aug; 39(4):344-6. PubMed ID: 1427580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of minoxidil in patients with cirrhosis and healthy volunteers.
    Adams MH; Poynor WJ; Garnett WR; Karnes HT; Ferry JJ; Ryan KK; Sarkar MA
    Biopharm Drug Dispos; 1998 Nov; 19(8):501-15. PubMed ID: 9840212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flecainide excretion in human breast milk.
    McQuinn RL; Pisani A; Wafa S; Chang SF; Miller AM; Frappell JM; Chamberlain GV; Camm AJ
    Clin Pharmacol Ther; 1990 Sep; 48(3):262-7. PubMed ID: 2119270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.